recent approvals in the nsclc treatment landscape
Published 2 years ago • 220 plays • Length 1:56Download video MP4
Download video MP3
Similar videos
-
2:19
the future of anti-pd-1 therapies in the nsclc treatment landscape
-
1:41
recent developments in the treatment of nsclc
-
0:49
recent drug approvals for nsclc
-
1:34
therapy sequencing in the current nsclc treatment landscape
-
44:56
advanced nsclc: refining clinical pathways in the rapidly evolving therapeutic landscape
-
2:53
the current treatment landscape for sclc
-
1:23
nsclc: a treatment landscape in flux in the checkpoint inhibitor era
-
15:25
targeted therapies: the future of non-small cell lung cancer (nsclc) treatment?
-
2:15
the impact of durvalumab for resectable non-small cell lung cancer
-
1:10
‘mixed bag’: only a fraction of recent drug approvals in nsclc space ‘considered practice changing’
-
1:58
future treatment landscape of nsclc
-
2:00
out of several recent drug approvals in nsclc, tabrecta most ‘practice changing’ of all
-
4:08
targeted therapies in lung cancer
-
3:28
the future of nsclc treatment
-
1:46
the evolving treatment landscape for nsclc with egfr exon 20 insertion mutations
-
4:37
advances in efgr-mutant nsclc treatment
-
0:57
what the future holds for antibodies in treating nsclc
-
2:34
key trials that will affect the therapy landscape for nsclc
-
1:50
pd-l1 agents in the treatment of nsclc